Instructions for Abbott models including: HF CRT-D Cardiac Resynchronization Therapy Devices, HF CRT-D, Cardiac Resynchronization Therapy Devices, Therapy Devices, Devices

Gallant™ HF CRT-D

19 mag 2024 — MR Conditional CRT-Ds are conditionally safe for use in the MRI environment when ... Refer to the User's Manual for detailed intended use, indications ...


File Info : application/pdf, 6 Pages, 202.47KB

PDF preview unavailable. Download the PDF instead.

Gallant-HF-CRT-D-DF-1-Header-Catalog-Page-v1
CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D)
GallantTM HF CRT-D
CDHFA500T

Compatible with myMerlinPulseTM app

Product Highlights
· Bluetooth® Low Energy (LE) communication enabling smartphone connectivity through data encryption
· MultiPointTM pacing delivers multiple LV pacing pulses per cardiac cycle in both LV only and BiV pacing modes
· SyncAVTM Plus CRT technology offers dynamic AV timing with adaptive programming to ensure BiV pacing with or without MultiPoint pacing
· Improved shape with reduced volume and thickness
· 40J delivered energy safety shock option for enhanced safety margin
· DeFT ResponseTM technology offers noninvasive programming options to optimize rescue therapy to each patient's unique physiology and changing conditions
· VF Therapy Assurance decreases the time to treatment for arrhythmias in patients who are likely to be hemodynamically unstable
· Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone further extends the programming options for terminating tachyarrhythmias without a high-voltage shock
· ShockGuardTM technology with DecisionTxTM programming is designed to reduce inappropriate therapy and minimize the need for programming adjustments at implant
­ SecureSenseTM RV lead noise discrimination algorithm detects sustained lead noise and short bursts of oversensing that would otherwise go unnoticed or potentially lead to one or more inappropriate shocks
­ Far Field MDTM morphology discrimination and chamber onset discrimination enhances SVT and VT discrimination for reduced inappropriate therapies
· SenseAbilityTM sensing algorithm feature provides the flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity

· The Gallant HF CRT-D and QuartetTM quadripolar LV lead feature four pacing electrodes and 13 pacing vectors to provide more options and greater control to address implant complications such as diaphragmatic stimulation and high pacing thresholds
· Easily test and program with Auto VectSelect QuartetTM multivector testing, offering an efficient workflow for complete results and programming
· DynamicTxTM over-current detection algorithm automatically changes shock configurations to ensure delivery of highvoltage therapy when high current is detected
· MRI-Ready device tested in combination with MR Conditional leads for full-body scans using a 1.5T or 3T (Tesla) field strength MRI Scanner*
· The CorVueTM thoracic impedance feature measures transthoracic impedance changes over time to provide additional insight into the patient's heart failure condition
· Cold can programmability provides an additional RV-SVC shock configuration to decouple the can from the shocking vector parameters in cases of lead problems
· Premature Atrial Contraction (PAC) Response to avoid pacing the atrium in a vulnerable zone
· Physiologic rate responsive AV Delay and PVARP
· QuickOptTM timing cycle optimization provides quick and effective optimization at the push of a button
· Dual patient notification: audio notification through the device and visual notification via myMerlinPulse app

GallantTM HF
CDHFA500T

CRT-D DEVICE

Ordering Information
Contents: Cardiac Pulse Generator

MODEL NUMBER

DIMENSIONS (L × W × H) (MM)

WEIGHT (G)

VOLUME (CC)

CONNECTOR DEFIBRILLATION

CONNECTOR SENSE/PACE

CDHFA500T

79 × 51 × 12

*See MRI Scan Parameters in MRI-Ready Systems Manual.

77

37

DF-1

IS-1

CONNECTOR PACE - LEFT VENTRICLE IS-4

Product Specifications

PARAMETER SPECIFICATIONS Model Telemetry Delivered/Stored Energy Volume Weight Size Defibrillation Lead Connection Atrial Sense/Pace Lead Connection Ventricular Sense/Pace Lead Connection Left Ventricular Pace Lead Connection High Voltage Can Parameter Biventricular Pacing VectSelect QuartetTM Programmable LV Pulse Configuration MultiPointTM Pacing
Delay MultiPoint Pacing
V. Triggering QuickOptTM Timing Cycle Optimization V-V Timing Interventricular Pace Delay Ventricular Sensing Ventricular Pacing Chamber SyncAVTM Plus CRT Technology Delta MPP PVAB AF Management AF SuppressionTM Pacing No. of Overdrive Pacing Cycles Maximum AF Suppression Rate

CDHFA500T Bluetooth® LE Communication 40/45 J 37 cc 77 g 79 × 51 × 12 mm DF-1
IS-1 in-line bipolar
IS-1 in-line bipolar
IS4-LLLL
Electrically active titanium can Settings
Distal Tip 1 - Mid 2; Distal Tip 1 - Proximal 4; Distal Tip 1 - Mid 3; Distal Tip 1 - RV Coil; Mid 2 - Mid 3; Mid 2 Proximal 4; Mid 2 - RV Coil; Mid 3 - Mid 2; Mid 3 - Proximal 4; Mid 3 - RV Coil; Proximal 4 - Mid 2; Proximal 4 - Mid 3: Proximal 4 - RV Coil LV1, LV2 Delay 1: 5; 10; ... 80 ms Delay 2: 5; 10; ... 50 ms On; Off
Sensed/Paced AV delay, Interventricular pace delay
Simultaneous; RV First; LV First RV First 10­80/LV First 15­80 ms RV only (not programmable) RV only; LV only; Biventricular If Type = Percentage: -10; - 15;...-70% If Type = Fixed: -10; -20;...-120 ms; Off 125-260 ms
On; Off 15-40 80-150 bpm

GallantTM HF
CDHFA500T

CRT-D DEVICE

Product Specifications

Sensing/Detection SenseAbilityTM Sensing Algorithm Low Frequency Attenuation
Threshold Start
Decay Delay
Ventricular Sense Refractory Detection Zones
SVT Discriminators
Monitor Mode Discrimination Modes SVT Upper Limit SVT Discrimination Timeout Reconfirmation SecureSenseTM RV Lead Noise Discrimination Algorithm VF Therapy Assurance Antitachycardia Pacing Therapy ATP Configurations ATP in VF Zone ATP Upper Rate Cutoff Burst Cycle Length Min. Burst Cycle Length Readaptive Number of Bursts/Stimuli Add Stimuli per Burst ATP Pulse Amplitude ATP Pulse Width High-Voltage Therapy DynamicTxTM Over-current Detection Algorithm DeFT ResponseTM Technology High-Voltage Output Mode Waveform RV Polarity Electrode Configuration Bradycardia Pacing Permanent Modes
Temporary Modes
Activity Sensor
Programmable Rate and Delay Parameters
Pulse Amplitude Pulse Width LVCapTM Confirm Feature, LVCapTM 2 Confirm Feature RVCapTM Confirm Feature

Automatic sensitivity control adjustment for atrial and ventricular events On; Off Post-Sensed: 50; 62.5; 75; 100% Post-Paced, Atrial: 0.2-3.0 mV Post-Paced, Ventricular: Auto, 0.2-3.0 mV Post-Sensed: 0-220 ms Post-Paced, Atrial: 0-220 ms Post-Paced, Ventricular: Auto, 0-220 ms 125; 157 ms 3 zone programming -- 1 zone; 2 zones; or 3 zones (VT-1; VT-2; VF) AV Rate Branch; Arrhythmia Onset (Chamber Onset or Sudden Onset); Interval Stability; AV Association Morphology; Discrimination (Far Field MDTM Morphology Discrimination or Original MD) with Automatic Template Update Detection, discrimination, and diagnostics, no therapy delivery (VT or VT-1 zone) On; Passive; Off 150-240 bpm 20s-60 min; Off Continuous sensing during charging
On; On with Timeout; Passive; Off
On; Off
Ramp; Burst; Scan; 1 or 2 schemes per VT zone ATP While Charging; ATP Prior to Charging; Off 150­300 bpm Adaptive (50%-100%); Fixed (200-550 ms) 150-400 in increments of 5 ms On; Off 1-15 with 2­20 Stimuli On; Off 7.5 V independent from bradycardia and post-therapy pacing 1.0 or 1.5 ms independently programmable from bradycardia and post-therapy pacing
On: Off
Programmable pulse width for P1/P2 and tilt Fixed Pulse Width; Fixed Tilt Biphasic; Monophasic Cathode (-); Anode (+) RV to Can; RV to SVC/Can; RV to SVC
DDD(R); DDT(R); DDI(R); VVT(R); VVI(R); AAI(R); Off DDD; DDT; DDI; VVT; VVI; AAI; AAT; DOO; VOO; AOO; Off On; Passive; Off Base Rate (bpm); Rest Rate (bpm); Maximum Tracking Rate (bpm); Max Trigger Rate (bpm); Maximum Sensor Rate (bpm); Paced AV Delay (ms); Sensed AV Delay (ms); Rate Responsive AV Delay; Hysteresis Rate (bpm); Rate Hysteresis with Search 0.25-7.5 V 0.05, 0.1-1.5 ms
Setup; On; Monitor; Off
Setup; On; Monitor; Off

GallantTM HF
CDHFA500T

CRT-D DEVICE

Product Specifications

Bradycardia Pacing

ACapTM Confirm Feature

On; Monitor; Off

Auto Mode Switch (AMS)

DDI(R); DDT(R); VVI(R); VVT(R); Off

Atrial Tachycardia Detection Rate 110-300 bpm

AMS Base Rate

40; 45; ... 135 bpm

PMT Detection/Termination

Atrial Pace; Passive; Off

Rate Responsive PVARP

Low; Medium; High; Off

Rate Responsive V Pace Refractory

On; Off

PAC Response

On; Off

PAC Response interval

200-400 ms

Shortest AV Delay

25-120 ms

Post-Therapy Pacing (Independently programmable from Bradycardia and ATP)

Post-Shock Pacing Mode

AAI; VVI; DDI; or DDD; Off

Post-Shock Base Rate

30-100 bpm

Post-Shock Pacing Duration

0.5; 1; 2.5; 5; 7.5; or 10 min; Off

Device Testing/Induction Methods

DC FibberTM Induction Method Pulse Duration

0.5-5.0 sec

Burst Fibber Cycle Length

20-100 ms

Noninvasive Programmed Stimulation (NIPS)

2-25 stimuli with up to 3 extra stimuli

Patient Notifiers

Programmable Notifiers (On; Off)

BatteryAssuranceTM alert; Possible HV circuit damage; HV charge timeout; Long charge time for Capacitor Maintenance; Device at ERI; Atrial pacing lead impedance out of range. Ventricular pacing lead impedance out of range; High-voltage lead impedance out of range; AT/AF Episode duration; AT/AF Burden; High ventricular rate during AT/AF; SecureSenseTM lead noise detection; Non-sustained ventricular oversensing; Ventricular pacing percentage greater than limit.

Device Parameter Reset

On

Entry into Backup VVI Mode

On

Auditory Duration

2; 4; 6; 8; 10; 12; 14; 16 sec

Number of Audio alerts per Notification

2

Number of Notifications

1­16

Time Between Notifications

10; 22 hours

Electrograms and Diagnostics

Stored Electrograms

30 minutes (2 user programmable + discrimination channel), up to 1 minute programmable pre-trigger data per VT/VF electrograms; additional triggers include lead noise detection, non-sustained ventricular oversensing, morphology template updates, atrial episode, PMT termination, PAC response, magnet reversion, noise reversion

Therapy Summary

Diagram of therapies delivered

Episodes Summary

Directory listing of up to 60 episodes with access to more details including stored electrograms

Lifetime Diagnostics

History of bradycardia events and device-initiated charging

AT/AF Burden Trend

Trend data and counts

Ventricular HV Lead Impedance Multi-Vector Trend Data

Histograms and Trends

Event Histogram; AV Interval Histogram; Mode Switch or AT/AF Duration Histogram; Peak Filtered Atrial Rate during Atrial Arrhythmia Histogram; Atrial Heart Rate Histogram; Ventricular Heart Rate Histogram; AT/AF Burden; Exercise and Activity Trending; V Rates during AMS; DirectTrendTM reports up to 1 year

PMT Data

Information regarding PMT detections

Real-Time Measurements (RTM) Pacing lead impedances; High-voltage lead impedances; Signal amplitudes

CorVue Thoracic Impedance

On; Off

CorVue Thoracic Impedance Threshold

8-18 days

GallantTM HF
CDHFA500T

CRT-D DEVICE

Product Specifications

MRI Settings Tachy Therapy MRI Mode MRI Base Rate MRI Paced AV Delay MRI RA and RV Pulse Amplitude MRI RA and RV Pulse Width MRI RA and RV Pulse Configuration
MRI LV Pulse Configuration
MRI LV Pulse Amplitude MRI LV Pulse Width MRI V Pacing Chamber MRI Timeout

Disabled DOO; VOO; AOO; Pacing Off 30-100 bpm 25-110 ms 5.0 or 7.5 V 1.0 ms
Bipolar
D1-M2, D1-M3, D1-P4, M2-M3, M2-P4, M3-M2, M3-P4, P4-M2, P4-M3 0.25-7.5 V 0.05-1.5 ms RV Only, LV+RV (Simultaneous) 3; 6; 9; 12; 24 hours; Off

MRI SCAN PARAMETERS Lead Model DurataTM Defibrillation Lead 7120 (lead lengths: 60, 65 cm) 7122 (lead lengths: 60, 65 cm) OptisureTM Lead LDA220 (lead lengths: 60, 65 cm) LDA210 (lead lengths: 60, 65 cm) QuartetTM LV Lead 1456Q (lead length: 86 cm) 1457Q (lead length: 86 cm) 1458Q (lead length: 86 cm) 1458QL (lead length: 86 cm) TendrilTM STS Pacing Lead 2088TC (lead lengths: 46, 52 cm) Tendril MRITM Lead LPA1200M (lead lengths: 46, 52 cm) UltiPace Pacemaker Lead LPA1231 (Lead lengths46, 52 cm)

Magnet (Tesla) 1.5 T / 3 T 1.5 T / 3 T
1.5 T / 3 T
1.5 T / 3 T 1.5 T 1.5 T / 3 T

RF Transmit Conditions

Scan Region

Normal Operating
Mode

Full-body

 LV first with 10 ms interventricular delay.
§ For additional information about specific MR Conditional CRT-Ds and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI-Ready Systems Manual at medical.abbott/manuals.

GallantTM HF
CDHFA500T

CRT-D DEVICE

Rx Only
Brief Summary: This product is intended for use by or under the direction of a Physician. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
Intended Use: The Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices are intended to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation. The CRT-D devices are also intended to resynchronize the right and left ventricles.
The myMerlinPulseTM mobile application is intended for use by people who have an Abbott Medical implanted heart device and access to a mobile device. The app provides remote monitoring capability of the implanted heart device by transmitting information from the patient's implanted heart device to the patient's healthcare provider.
Indications: The CRT-D devices are indicated for automated treatment of life-threatening ventricular arrhythmias. CRT-D devices are also indicated to treat symptoms in patients who have congestive heart failure with ventricular dyssynchrony.
In addition, dual chamber CRT-D devices with the AT/AF detection algorithm are indicated in patients with atrial tachyarrhythmias or those patients who are at significant risk of developing atrial tachyarrhythmias.
MR Conditional CRT-Ds are conditionally safe for use in the MRI environment when used in a complete MR Conditional system and according to instructions in the MRI-Ready Systems manual. Scanning under different conditions may result in severe patient injury, death or device malfunction.
The myMerlinPulseTM mobile application is indicated for use by patients with supported Abbott Medical implanted heart devices.
Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction.
The myMerlinPulseTM mobile application is contraindicated for use with any implanted medical device other than supported Abbott Medical implanted heart devices.
Adverse Events: Possible adverse events associated with the implantation of the pulse generator system include the following: Arrhythmia (for example, accelerated or induced), Bradycardia, Cardiac or venous perforation, Cardiac tamponade, Cardiogenic shock, Death, Discomfort, Embolism, Endocarditis, Erosion, Exacerbation of heart failure, Excessive fibrotic tissue growth, Extracardiac stimulation (phrenic nerve, diaphragm, pectoral muscle), Extrusion, Fluid accumulation within the device pocket, Formation of hematomas, cysts, or seromas, Heart block, Hemorrhage, Hemothorax, Hypersensitivity, including local tissue reaction or allergic reaction, Infection, Keloid formation, Myocardial damage, Nerve damage, Occlusion/Thrombus, Pericardial effusion, Pericarditis, Pneumothorax, Pulmonary edema, Syncope, Thrombosis, Valve damage. Complications reported with direct subclavian venipuncture include pneumothorax, hemothorax, laceration of the subclavian artery, arteriovenous fistula, neural damage, thoracic duct injury, cannulation of other vessels, massive hemorrhage and rarely, death. Among the psychological effects of device implantation are imagined pulsing, depression, dependency, fear of premature battery depletion, device malfunction, inappropriate pulsing, shocking while conscious, or losing pulse capability. Possible adverse device effects include complications due to the following: , Abnormal battery depletion, Conductor fracture, Device-programmer communication failure, Elevated or rise in defibrillation/cardioversion threshold, Inability to defibrillate or pace, Inability to interrogate or program due to programmer or device malfunction, Incomplete lead connection with pulse generator, Inhibited therapy including defibrillation and pacing, Inappropriate therapy (for example, shocks and antitachycardia pacing [ATP] where applicable, pacing), Interruption of function due to electrical or magnetic interference, Intolerance to high rate pacing (for example dyspnea or discomfort), Lead abrasion, Lead fracture, Lead insulation damage, Lead migration or lead dislodgement, Loss of device functionality due to component failure, Pulse generator migration, Rise in DFT threshold, Rise in pacing threshold and exit block, Shunting of energy from defibrillation paddles, System failure due to ionizing radiation. Additionally, potential adverse events associated with the implantation of a coronary venous lead system include the following: Allergic reaction to contrast media, Breakage or failure of implant instruments, Prolonged exposure to fluoroscopic radiation, Renal failure from contrast media used to visualize coronary veins. Refer to the User's Manual for detailed intended use, indications, contraindications, warnings, precautions and potential adverse events.
No potential adverse events have been identified with use of the myMerlinPulseTM mobile application.

Abbott 15900 Valley View Court, Sylmar, CA 91342 Tel: +1 818 362 6822 Abbott.com
TM Indicates a trademark of the Abbott group of companies.  Indicates a third party trademark, which is property of its respective owner.
© 2024 Abbott. All Rights Reserved. MAT-2400585 v1.0 | Item approved for U.S. only.



References

Adobe PDF Library 17.0 Adobe InDesign 19.1 (Macintosh)